Mandate

Investor buys out part of Neoventa Medical

July 21, 2006

Investor Growth Capital and CapMan are investing in Neoventa Medical AB, a Swedish medical technology company in the field of fetal monitoring. Investor Growth Capital and CapMan will hold approximately 30% each of the share capital, while the majority of the remaining shares will be owned by SEK Företagsinvest as previous. The new ownership constellation provides the company with SEK 75 million to finance the next phase in Neoventa's growth - focusing on the American market.

Vinge acted as advisor to Neoventa Holding AB. Vinge representatives included Johan Winnerblad, Marcus Axelryd and Theresa Kovac.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026